Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Stocktwits on MSN
Regeneron’s drug combo fails to prove superiority over Merck’s Keytruda in melanoma
While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how ...
Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of ...
Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...
A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings ...
Mounjaro surpasses Keytruda top sales with $8.7B in Q1 2025, marking a 125% increase for Eli Lilly over Merck's cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results